Trellis Bioscience
Trellis Bioscience, Inc.
Trellis Bioscience is developing native human antibodies to disrupt bacterial biofilms and address difficult-to-treat infections.
trellisbio.com · Redwood City, CA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$22.9M of Indefinite
Filed2026-10-21
Days since filing23
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2010-04-29
Investors
No investors named: Form D does not list them
This round was amended. Amendment filing
Officers on the filing
Names and roles as filed; addresses are never stored- Nora MendeExecutive Officer
- Larry KauvarExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$9.1M sold25.3 months since first sale
Prior raiseNot flaggedRaised $9.1M against a prior $6.1M$6.1M prior raise, filed 2026-05-15
AmendedNot flaggedD/A on 2026-10-29Amount offered unchanged or not stated
Open roles
On the employer's own careers page · checked 2026-10-310
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
All filings
Every filing for this company, newest first, amendments includedAlso raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.